Misplaced Pages

Aleniglipron

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from GSBR-1290) Chemical compound
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Pharmaceutical compound
Aleniglipron
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 3--2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2-(4-fluoro-3,5-dimethylphenyl)-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolopyridin-5-yl]carbonyl]-5-(tetrahydro-2H-pyran-4-yl)-1H-indol-1-yl]-2-methylcyclopropyl]-1,2,4-oxadiazol-5(2H)-one
CAS Number
PubChem CID
DrugBank
UNII
Chemical and physical data
FormulaC49H55FN9O6P
Molar mass916.008 g·mol
InChI
  • InChI=1S/C49H55FN9O6P/c1-8-66(63,9-2)41-13-11-35(26-38(41)51-7)56-18-19-57(48(56)62)44-42-31(6)55(17-14-37(42)53-59(44)36-22-28(3)43(50)29(4)23-36)45(60)40-25-34-24-33(32-15-20-64-21-16-32)10-12-39(34)58(40)49(27-30(49)5)46-52-47(61)65-54-46/h10-13,18-19,22-26,30-32,51H,8-9,14-17,20-21,27H2,1-7H3,(H,52,54,61)/t30-,31-,49-/m0/s1
  • Key:CPOJUYUGONJVPZ-WIXASUBBSA-N

Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics. It is delivered orally and is in a Phase II trial as of 2023. In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.

References

  1. Mao, Ting; Meng, Qinghua; Zhang, Haizhen; Zhang, Jinqiang J.; Shi, Songting; Guan, Zhibo; Jiang, Xinglong; Zhang, Fang; Lei, Hui; Lin, Xichen (20 June 2023). "760-P: Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist". Diabetes. 72 (Supplement_1). doi:10.2337/db23-760-P. S2CID 259430363.
  2. "Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity". BioSpace. 25 May 2023. Retrieved 4 November 2023.
  3. "Structure announces positive results from oral GLP-1 receptor agonist gsbr-1290". Bariatric News. 2 October 2023. Retrieved 4 November 2023.
  4. Satija, Bhanvi (29 September 2023). "Structure Therapeutics surges as early data from obesity pill tops expectations". Reuters. Retrieved 4 November 2023.
  5. "Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290". BioSpace. 2024-06-03. Retrieved 2024-10-24.
Categories:
Aleniglipron Add topic